---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-067660"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:50:40.556769+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics shareholders approve 1M share increase to equity plan, elect two new directors

## Summary
- Amendment to 2018 Stock Option Plan adding 1,000,000 common shares to reserve approved (34.3M for, 8.5M against).
- Sandesh Mahatme and Christian Rommel elected as new Board members; all incumbent directors re-elected.
- Articles of Association amended: capital band increased to CHF 3,100,452; equity/pension practices updated.
- Binding vote on Board equity grants passed 32.2M for vs 10.7M against; 2023 compensation report endorsed non-binding.
- Proposal to transact other business was rejected (21.9M against, 20.3M for).

## SEC filing metadata
- accession: 0000950170-24-067660
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017024067660/0000950170-24-067660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017024067660/crsp-20240530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-067660
- JSON: https://secwatch.observer/filing/0000950170-24-067660.json
- Plain text: https://secwatch.observer/filing/0000950170-24-067660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.